Cairo – Mubasher: The board of directors of GlaxoSmithKline (GSK Egypt) approved a fair value (FV) report prepared by the independent financial advisor Grant Thornton - Egypt for the consumer health business assets.
These assets include the relevant intangible and movable assets, excluding real estate and machinery, the company said in a statement to the Egyptian Exchange (EGX) on Wednesday.
The independent financial advisor valued these assets at EGP 1.179 billion, the statement showed.
In the first half (H1) of 2021, the company reported consolidated net profits of EGP 20.63 million, down from EGP 115.96 million in H1-20, including minority shareholders' rights.
Source: Mubasher
All Rights Reserved - Mubasher Info © 2005 - 2021 Provided by SyndiGate Media Inc. (Syndigate.info).
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
